TriSalus Life Sciences has announced the publication of preclinical data in the Journal of Vascular and Interventional Radiology, demonstrating improved delivery of Embospheres to liver tumors using its Pressure Enabled Drug Delivery (PEDD) via the TriNav Infusion System. The study, conducted in a transgenic porcine tumor model, compared TriNav's performance against traditional microcatheters.
The research, titled "Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model," revealed that PEDD achieved a 227% increase (p=0.029) in the concentration of fluorescently labeled Embospheres within tumor tissue compared to traditional microcatheter delivery. This indicates a significant improvement in tumor penetration.
Enhanced Tumor Selectivity and Reduced Off-Target Delivery
Furthermore, the study highlighted improved tumor selectivity with PEDD. The tumor-to-normal (T:N) ratio increased from 2.7 for traditional microcatheters to 4.2 when using PEDD. This suggests that the TriNav system allows for more precise tumor targeting, reducing the exposure of healthy tissue to the therapeutic agent.
Increased Peritumoral Delivery
Delivery to peritumoral regions also saw a substantial increase of 209% (p=0.045) with PEDD. This finding demonstrates PEDD's potential to overcome challenges posed by tumor-associated microenvironments, which can often hinder effective drug delivery.
Expert Commentary
"This study further validates the potential of TriNav using the PEDD approach to transform the treatment of liver tumors," said Bryan F. Cox, Ph.D., Chief of Research for TriSalus. "By significantly enhancing therapeutic delivery and sparing healthy tissue, PEDD offers a promising advancement for patients whose outcomes may be limited by conventional delivery methods."
The study utilized a transgenic porcine (Oncopig) liver tumor model, employing fluorescent imaging and advanced deep-learning algorithms to quantify therapeutic delivery with millimeter-scale resolution. The results showed that the TriNav Infusion System, when used with the PEDD approach, markedly outperformed traditional microcatheters in delivering embolic microspheres into liver tumors.
These findings contribute to the growing body of clinical and real-world evidence supporting PEDD's ability to improve the delivery of therapeutic agents for patients with primary and metastatic liver cancers. TriSalus Life Sciences aims to improve therapeutic delivery to solid tumors through its disruptive drug delivery technology. The company's platform includes devices that utilize its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics.
